Who
David D. Chang
President and CEO
Company insider
Files Form 4 as: President and CEO, Allogene Therapeutics; EVP, R&D, Chief Medical Off., Kite Pharma.
In numbers
- Trades disclosed
- 129
- Buys
- 2
- Sells
- 20
- Bought
- $788K
- Sold
- $17.0M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 25 Jun 2014
- Last trade
- 16 Mar 2026
- Last filed
- 18 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Mar 2026filed 18 Mar 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $118K47,763 at $2.47 | filing |
| 16 Mar 2026filed 18 Mar 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $118K47,763 at $2.47 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $171K95,269 at $1.80 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,387,931 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —392,586 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,387,931 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —392,586 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $171K95,269 at $1.80 | filing |
| 14 Mar 2025filed 18 Mar 2025 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $91K46,668 at $1.96 | filing |
| 3 Feb 2025filed 5 Feb 2025 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $77K46,003 at $1.68 | filing |
| 24 Jan 2025filed 28 Jan 2025 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,952,130 at $0.00 | filing |
| 24 Jan 2025filed 28 Jan 2025 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —552,174 at $0.00 | filing |
| 16 May 2024filed 20 May 2024 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | $1.0M344,828 at $2.90 | filing |
| 14 Mar 2024filed 18 Mar 2024 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code F | $231K53,393 at $4.33 | filing |
| 25 Jan 2024filed 31 Jan 2024 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,123,535 at $0.00 | filing |
| 25 Jan 2024filed 31 Jan 2024 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —317,800 at $0.00 | filing |
| 22 Mar 2023filed 24 Mar 2023 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,492,200 at $0.00 | filing |
| 22 Mar 2023filed 24 Mar 2023 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,924,464 at $0.00 | filing |
| 14 Mar 2023filed 16 Mar 2023 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code F | $124K22,340 at $5.56 | filing |
| 23 Mar 2022filed 25 Mar 2022 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,195,512 at $0.00 | filing |
News
Comparing eXoZymes (NASDAQ:EXOZ) and Allogene Therapeutics (NASDAQ:ALLO)ALLO · dailypolitical.com · 16 Oct 2026
0 headlines in the last 90 days name David D. Chang; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.